"Staurosporine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An indolocarbazole that is a potent PROTEIN KINASE C inhibitor which enhances cAMP-mediated responses in human neuroblastoma cells. (Biochem Biophys Res Commun 1995;214(3):1114-20)
Descriptor ID |
D019311
|
MeSH Number(s) |
D03.132.436.750 D03.633.100.473.144.750 D03.633.100.473.402.750 D03.633.300.148.750
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Staurosporine".
Below are MeSH descriptors whose meaning is more specific than "Staurosporine".
This graph shows the total number of publications written about "Staurosporine" by people in this website by year, and whether "Staurosporine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 0 | 1 | 1 |
1995 | 0 | 1 | 1 |
1996 | 0 | 1 | 1 |
1997 | 1 | 0 | 1 |
1998 | 0 | 1 | 1 |
1999 | 0 | 2 | 2 |
2000 | 0 | 4 | 4 |
2002 | 0 | 1 | 1 |
2004 | 0 | 3 | 3 |
2005 | 1 | 0 | 1 |
2009 | 0 | 1 | 1 |
2012 | 0 | 1 | 1 |
2017 | 2 | 0 | 2 |
2018 | 1 | 0 | 1 |
2020 | 0 | 1 | 1 |
2021 | 2 | 0 | 2 |
2022 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Staurosporine" by people in Profiles.
-
Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications. Blood Adv. 2022 09 27; 6(18):5345-5355.
-
Minimizing Molecular Misidentification in Imaging Low-Abundance Protein Interactions Using Spectroscopic Single-Molecule Localization Microscopy. Anal Chem. 2022 10 11; 94(40):13834-13841.
-
Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin. Blood. 2021 06 03; 137(22):3093-3104.
-
Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial. Leukemia. 2021 09; 35(9):2539-2551.
-
Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial. Blood Adv. 2020 10 13; 4(19):4945-4954.
-
Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis. Blood Adv. 2018 02 27; 2(4):444-453.
-
Midostaurin in FLT3-Mutated Acute Myeloid Leukemia. N Engl J Med. 2017 11 09; 377(19):1903.
-
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. N Engl J Med. 2017 08 03; 377(5):454-464.
-
Overexpression of the Insulin-Like Growth Factor II Receptor Increases ß-Amyloid Production and Affects Cell Viability. Mol Cell Biol. 2015 Jul; 35(14):2368-84.
-
H2O2 production downstream of FLT3 is mediated by p22phox in the endoplasmic reticulum and is required for STAT5 signalling. PLoS One. 2012; 7(7):e34050.